As the Educational Medical Director for Age Diagnostics Laboratories in Chicago, Dr. Binyamin Rothstein worked to educate physicians in the interpretation and use of laboratory services. This work in the causes and symptoms of aging prompted increased interest in medical research into aging for Dr. Rothstein.
Dr. Rothstein developed an expertise in MTHFR deficiency, and developed Vitaben’s vitamins to help counteract the effects of this common enzyme deficiency. Methylene tetrahydrofolate reductase (MTHFR) is a rate limiting enzyme enabled by the MTHFR gene. Studies are ongoing into the influence of MTHFR deficiency on susceptibility to vascular disease, neural tube defects, Alzheimer’s disease and other possible forms of dementia, cancer and leukemia.
Research on mutations in the MTHFR gene has indicated possible risk factors for schizophrenia. There are also possible links to mutations in the gene as a probable cause of dementia, as indicated in a study involving elderly Japanese populations which showed links between a specific mutation of the gene, C677T, and types of senile dementia. In addition, mutations related to lack of folic acid and the effect on functional deficiency has been indicated in research. Dr. Binyamin Rothstein has used his research knowledge of genetic mutation and MTHFR to develop alternative supplement treatments for those suffering from the effects of dementia and Alzheimer’s.
A 2011 Chinese study found C677T SNP associated with Alzheimer’s disease in Asian populations. Patients with severe MTHFR deficiency may exhibit developmental delay, motor and gait dysfunction, seizures, and neurological impairment, further support for the supplement protocol of Dr. Binyamin Rothstein.